Media stories about ENDRA Life Sciences (NASDAQ:NDRA) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ENDRA Life Sciences earned a news impact score of 0.09 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.0357170181113 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
ENDRA Life Sciences (NDRA) opened at $2.50 on Wednesday. ENDRA Life Sciences has a 52-week low of $2.20 and a 52-week high of $4.00.
About ENDRA Life Sciences
ENDRA Life Sciences Inc develops photo- and thermo-acoustic medical technologies that bring new capabilities to existing ultrasound systems. Its photo-acoustic solutions help global medical researchers to screen and modify disease models with high image quality and volume scanning speed. The company offers the Nexus-128 system, a fully 3D imaging solution for imaging anatomy, physiology, and labeled molecular targets for institutions.
Receive News & Ratings for ENDRA Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.